Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HEPA NASDAQ:ORGS NASDAQ:PBLA NASDAQ:SMFL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEPAHepion Pharmaceuticals$0.07-17.1%$0.06$0.03▼$0.08$763K1.5288,529 shs36,073 shsORGSOrgenesis$1.00$0.84$0.00▼$7.50$4.80M0.447,109 shsN/APBLAPanbela Therapeutics$0.16$0.18$0.05▼$0.47$767K1.3316,242 shs3 shsSMFLSmart for Life$0.01+636.4%$0.01$0.00▼$1.56$57K17.056,199 shs672 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEPAHepion Pharmaceuticals0.00%+21.49%+58.81%+2.62%-99.84%ORGSOrgenesis0.00%+900.00%+4,445.45%-48.45%+99,999,900.00%PBLAPanbela Therapeutics0.00%0.00%-7.12%-38.80%-56.48%SMFLSmart for Life0.00%+145.45%+92.86%+1,925.00%-99.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHEPAHepion Pharmaceuticals0.4602 of 5 stars0.05.00.00.00.60.00.6ORGSOrgenesis1.6998 of 5 stars0.03.00.04.42.00.00.0PBLAPanbela Therapeutics0.235 of 5 stars0.05.00.00.00.60.00.0SMFLSmart for LifeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHEPAHepion Pharmaceuticals 0.00N/AN/AN/AORGSOrgenesis 0.00N/AN/AN/APBLAPanbela Therapeutics 0.00N/AN/AN/ASMFLSmart for Life 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/AORGSOrgenesis$662K7.25N/AN/A($6.58) per share-0.15PBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/ASMFLSmart for Life$11.11M0.01N/AN/A($17.10) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%11/12/2025 (Estimated)ORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%11/11/2025 (Estimated)PBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%11/12/2025 (Estimated)SMFLSmart for Life-$22.68MN/A0.00∞N/AN/AN/AN/AN/ALatest SMFL, ORGS, PBLA, and HEPA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2025Q3 2024SMFLSmart for LifeN/A-$0.94N/A-$0.94N/A$1.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ASMFLSmart for LifeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHEPAHepion PharmaceuticalsN/A1.301.30ORGSOrgenesisN/A0.070.07PBLAPanbela TherapeuticsN/A0.260.26SMFLSmart for LifeN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHEPAHepion Pharmaceuticals17.24%ORGSOrgenesis22.56%PBLAPanbela Therapeutics4.37%SMFLSmart for Life28.39%Insider OwnershipCompanyInsider OwnershipHEPAHepion Pharmaceuticals0.06%ORGSOrgenesis5.66%PBLAPanbela Therapeutics0.01%SMFLSmart for Life31.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHEPAHepion Pharmaceuticals2011.44 million6.63 millionNo DataORGSOrgenesis1504.80 million4.53 millionNo DataPBLAPanbela Therapeutics64.86 million4.86 millionNot OptionableSMFLSmart for Life1107.09 million4.84 millionNot OptionableSMFL, ORGS, PBLA, and HEPA HeadlinesRecent News About These CompaniesSmart for Life Inc. (SMFL) Analyst ResearchMarch 21, 2025 | nasdaq.comHere’s How ‘Smart Cities’ Focus On Resilience And Growth No Matter Who’s PresidentNovember 14, 2024 | forbes.comSMART High School Common App WorkshopOctober 26, 2024 | volunteermatch.orgV7 Smart Tips for Living a Joyful and Purpose-Driven LifeOctober 4, 2024 | fingerlakes1.comFLucky for Life prize worth $25K a year for life won for 3rd time in a weekSeptember 30, 2024 | mlive.comMMaximize Your Products' Lifespan with These Smart TricksSeptember 29, 2024 | msn.comSmart for Life Reports Significant Balance Sheet Improvement; Achieves Over $9.4 Million in Positive Net Stockholders' Equity Following Successful Restructuring EffortsSeptember 23, 2024 | globenewswire.comSmart for Life Provides Update Following Nasdaq Delisting Due to Audit Delays; Reports Plans to Reapply to Nasdaq Upon Full ComplianceSeptember 20, 2024 | globenewswire.comEufy’s Matter-enabled smart lock is 30% off todaySeptember 19, 2024 | msn.comSmart for Life Inc (SMFL) Stock Price Reaches $0.78: What Factors Are Influencing This Level?September 19, 2024 | bovnews.comBEufy’s new smart lock may Matter to Apple Home usersSeptember 18, 2024 | msn.comSmart supramolecular assembliesSeptember 18, 2024 | sciencedaily.comSLIFX A21 SuperColor Smart Light review: Affordable Hue alternativeSeptember 16, 2024 | yahoo.comEufy’s new smart lock is the company’s first with Matter supportSeptember 16, 2024 | msn.comSmart Homes for the Elderly: Making Life Easier and SaferSeptember 16, 2024 | msn.comSmart for Life Inc (SMFL) Stock: More Resilient Than It AppearsSeptember 13, 2024 | bovnews.comBInsider Buying: Smart for Life, Inc. (NASDAQ:SMFL) Major Shareholder Buys 17,722 Shares of StockSeptember 12, 2024 | insidertrades.comHRT Financial LP Acquires New Stake in Smart for Life IncSeptember 12, 2024 | finance.yahoo.comSmart For Life Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 9, 2024 | markets.businessinsider.comSmart for Life Inc (SMFL) Stock: Surpassing Expectations in the MarketSeptember 2, 2024 | bovnews.comBNew MarketBeat Followers Over TimeSMFL, ORGS, PBLA, and HEPA Company DescriptionsHepion Pharmaceuticals NASDAQ:HEPA$0.07 -0.01 (-17.14%) As of 08/29/2025 03:52 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Orgenesis NASDAQ:ORGS$1.00 0.00 (0.00%) As of 08/29/2025Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Panbela Therapeutics NASDAQ:PBLA$0.16 0.00 (0.00%) As of 08/29/2025Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.Smart for Life NASDAQ:SMFL$0.0081 +0.01 (+636.36%) As of 08/29/2025 03:27 PM EasternSmart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
